Bile acid-mediated control of liver triglycerides

Seminars in Liver Disease

Volumn 33, Issue 4, 2013, Pages 330-342

  Fuchs, Claudia ^a   Claudel, Thierry ^a   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

farnesoid X receptor; FGF15 19 21; glucose; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; TGR5

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BILE ACID; CHOLESTEROL; FARNESOID X RECEPTOR; FIBRINOGEN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 1C; FIBROBLAST GROWTH FACTOR 21; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 5; GLUCOSE; OBETICHOLIC ACID; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PX 20606; TRIACYLGLYCEROL; TUROFEXORATE ISOPROPYL; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ARTICLE; ATHEROSCLEROSIS; BILE ACID SYNTHESIS; DOWNSTREAM PROCESSING; DRUG MEGADOSE; ENTEROHEPATIC CIRCULATION; FIBRINOGEN BLOOD LEVEL; HUMAN; LIPID ABSORPTION; LIPID LIVER LEVEL; METABOLIC REGULATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BILE ACIDS AND SALTS; FATTY LIVER; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 84887599824     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1358520     Document Type: Article

References (165)

1. Trauner M., Boyer J. L. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev: 2003; 83 2 633 671
2. Kullak-Ublick G. A., Beuers U., Paumgartner G. Hepatobiliary transport. J Hepatol: 2000; 32 (1, Suppl) 3 18
3. Hagenbuch B., Meier P. J. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest: 1994; 93 3 1326 1331
4. Kullak-Ublick G. A., Hagenbuch B., Stieger B., Wolkoff A. W., Meier P. J. Functional characterization of the basolateral rat liver organic anion transporting polypeptide. Hepatology: 1994; 20 2 411 416
5. Hofmann A. F. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med: 1999; 159 22 2647 2658
6. Russell D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem: 2003; 72 137 174
7. Leiss O., von Bergmann K. Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. Scand J Gastroenterol: 1982; 17 5 587 592
8. Duane W. C. Abnormal bile acid absorption in familial hypertriglyceridemia. J Lipid Res: 1995; 36 1 96 107
9. Duane W. C., Hartich L. A., Bartman A. E., Ho S. B. Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J Lipid Res: 2000; 41 9 1384 1389
10. Angelin B. 1994 Mack-Forster Award Lecture. Review. Studies on the regulation of hepatic cholesterol metabolism in humans. Eur J Clin Invest: 1995; 25 4 215 224
11. Angelin B., Einarsson K., Hellström K., Leijd B. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J Lipid Res: 1978; 19 8 1017 1024
12. Mölgaard J., von Schenck H., Olsson A. G. Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia. Eur J Clin Pharmacol: 1989; 36 5 455 460
13. Buchwald H., Varco R. L., Matts J. P., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med: 1990; 323 14 946 955
14. Donnelly K. L., Smith C. I., Schwarzenberg S. J., Jessurun J., Boldt M. D., Parks E. J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest: 2005; 115 5 1343 1351
15. Cohen J. C., Horton J. D., Hobbs H. H. Human fatty liver disease: old questions and new insights. Science: 2011; 332 6037 1519 1523
16. Horton J. D., Goldstein J. L., Brown M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest: 2002; 109 9 1125 1131
17. Nguyen P., Leray V., Diez M., et al. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl): 2008; 92 3 272 283
18. Tiwari S., Siddiqi S. A. Intracellular trafficking and secretion of VLDL. Arterioscler Thromb Vasc Biol: 2012; 32 5 1079 1086
19. Houten S. M., Watanabe M., Auwerx J. Endocrine functions of bile acids. EMBO J: 2006; 25 7 1419 1425
20. Hylemon P. B., Zhou H., Pandak W. M., Ren S., Gil G., Dent P. Bile acids as regulatory molecules. J Lipid Res: 2009; 50 8 1509 1520
21. Wagner M., Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis. Ann Hepatol: 2005; 4 2 77 99
22. Claudel T., Staels B., Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol: 2005; 25 10 2020 2030
23. Parks D. J., Blanchard S. G., Bledsoe R. K., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science: 1999; 284 5418 1365 1368
24. Makishima M., Okamoto A. Y., Repa J. J., et al. Identification of a nuclear receptor for bile acids. Science: 1999; 284 5418 1362 1365
25. Wang H., Chen J., Hollister K., Sowers L. C., Forman B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell: 1999; 3 5 543 553
26. Sayin S. I., Wahlström A., Felin J., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab: 2013; 17 2 225 235
27. Chiang J. Y. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev: 2002; 23 4 443 463
28. Chiang J. Y. Bile acids: regulation of synthesis. J Lipid Res: 2009; 50 10 1955 1966
29. Watanabe M., Houten S. M., Mataki C., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature: 2006; 439 7075 484 489
30. Thomas C., Pellicciari R., Pruzanski M., Auwerx J., Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov: 2008; 7 8 678 693
31. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev: 2009; 89 1 147 191
32. Chiang J. Y. Nuclear receptor regulation of lipid metabolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases. Curr Opin Investig Drugs: 2005; 6 10 994 1001
33. Claudel T., Sturm E., Duez H., et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest: 2002; 109 7 961 971
34. Barbier O., Torra I. P., Sirvent A., et al. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology: 2003; 124 7 1926 1940
35. Laffitte B. A., Kast H. R., Nguyen C. M., Zavacki A. M., Moore D. D., Edwards P. A. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem: 2000; 275 14 10638 10647
36. Claudel T., Inoue Y., Barbier O., et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology: 2003; 125 2 544 555
37. Zollner G., Marschall H. U., Wagner M., Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm: 2006; 3 3 231 251
38. Eloranta J. J., Kullak-Ublick G. A. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys: 2005; 433 2 397 412
39. Landrier J. F., Eloranta J. J., Vavricka S. R., Kullak-Ublick G. A. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am J Physiol Gastrointest Liver Physiol: 2006; 290 3 G476 G485
40. Lee H., Zhang Y., Lee F. Y., Nelson S. F., Gonzalez F. J., Edwards P. A. FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J Lipid Res: 2006; 47 1 201 214
41. Holt J. A., Luo G., Billin A. N., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev: 2003; 17 13 1581 1591
42. Inagaki T., Choi M., Moschetta A., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab: 2005; 2 4 217 225
43. Sinal C. J., Tohkin M., Miyata M., Ward J. M., Lambert G., Gonzalez F. J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell: 2000; 102 6 731 744
44. Watanabe M., Houten S. M., Wang L., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest: 2004; 113 10 1408 1418
45. Pineda Torra I., Claudel T., Duval C., Kosykh V., Fruchart J. C., Staels B. Bile acids induce the expression of the human peroxisome proliferator- activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol: 2003; 17 2 259 272
46. Hirokane H., Nakahara M., Tachibana S., Shimizu M., Sato R. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem: 2004; 279 44 45685 45692
47. Kast H. R., Nguyen C. M., Sinal C. J., et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol: 2001; 15 10 1720 1728
48. Prieur X., Coste H., Rodriguez J. C. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem: 2003; 278 28 25468 25480
49. Lambert G., Amar M. J., Guo G., Brewer H. B. Jr, Gonzalez F. J., Sinal C. J. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem: 2003; 278 4 2563 2570
50. Rizzo G., Disante M., Mencarelli A., et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol: 2006; 70 4 1164 1173
51. Abdelkarim M., Caron S., Duhem C., et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem: 2010; 285 47 36759 36767
52. Ma K., Saha P. K., Chan L., Moore D. D. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest: 2006; 116 4 1102 1109
53. Düfer M., Hörth K., Wagner R., et al. Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes: 2012; 61 6 1479 1489
54. Stayrook K. R., Bramlett K. S., Savkur R. S., et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology: 2005; 146 3 984 991
55. Zhang Y., Lee F. Y., Barrera G., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A: 2006; 103 4 1006 1011
56. Kir S., Beddow S. A., Samuel V. T., et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science: 2011; 331 6024 1621 1624
57. Cariou B., van Harmelen K., Duran-Sandoval D., et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem: 2006; 281 16 11039 11049
58. Cariou B., van Harmelen K., Duran-Sandoval D., et al. Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett: 2005; 579 19 4076 4080
59. Nishimura T., Utsunomiya Y., Hoshikawa M., Ohuchi H., Itoh N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta: 1999; 1444 1 148 151
60. Tomlinson E., Fu L., John L., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology: 2002; 143 5 1741 1747
61. Ha J., Lee J. K., Kim K. S., Witters L. A., Kim K. H. Cloning of human acetyl-CoA carboxylase-beta and its unique features. Proc Natl Acad Sci U S A: 1996; 93 21 11466 11470
62. Abu-Elheiga L., Matzuk M. M., Abo-Hashema K. A., Wakil S. J. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science: 2001; 291 5513 2613 2616
63. Huang X., Yang C., Luo Y., Jin C., Wang F., McKeehan W. L. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes: 2007; 56 10 2501 2510
64. Ntambi J. M., Miyazaki M., Stoehr J. P., et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A: 2002; 99 17 11482 11486
65. Lundåsen T., Gälman C., Angelin B., Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med: 2006; 260 6 530 536
66. Li T., Chiang J. Y. Bile acid signaling in liver metabolism and diseases. J Lipids: 2012; 2012 754067
67. Schreuder T. C., Marsman H. A., Lenicek M., et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol: 2010; 298 3 G440 G445
68. Bange J., Prechtl D., Cheburkin Y., et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res: 2002; 62 3 840 847
69. Huang X., Yu C., Jin C., et al. Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res: 2006; 66 3 1481 1490
70. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta: 2000; 1492 1 203 206
71. Kurosu H., Choi M., Ogawa Y., et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem: 2007; 282 37 26687 26695
72. Ogawa Y., Kurosu H., Yamamoto M., et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A: 2007; 104 18 7432 7437
73. Suzuki M., Uehara Y., Motomura-Matsuzaka K., et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol: 2008; 22 4 1006 1014
74. Kharitonenkov A., Shiyanova T. L., Koester A., et al. FGF-21 as a novel metabolic regulator. J Clin Invest: 2005; 115 6 1627 1635
75. Huang X., Yu C., Jin C., et al. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog: 2006; 45 12 934 942
76. Wente W., Efanov A. M., Brenner M., et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes: 2006; 55 9 2470 2478
77. Badman M. K., Pissios P., Kennedy A. R., Koukos G., Flier J. S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab: 2007; 5 6 426 437
78. Inagaki T., Dutchak P., Zhao G., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab: 2007; 5 6 415 425
79. Cyphert H. A., Ge X., Kohan A. B., Salati L. M., Zhang Y., Hillgartner F. B. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem: 2012; 287 30 25123 25138
80. Zhang X., Yeung D. C., Karpisek M., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes: 2008; 57 5 1246 1253
81. Chen W. W., Li L., Yang G. Y., et al. Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes: 2008; 116 1 65 68
82. Genet C., Strehle A., Schmidt C., et al. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem: 2010; 53 1 178 190
83. Kawamata Y., Fujii R., Hosoya M., et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem: 2003; 278 11 9435 9440
84. Vassileva G., Golovko A., Markowitz L., et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J: 2006; 398 3 423 430
85. Keitel V., Cupisti K., Ullmer C., Knoefel W. T., Kubitz R., Häussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology: 2009; 50 3 861 870
86. Maruyama T., Miyamoto Y., Nakamura T., et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun: 2002; 298 5 714 719
87. Keitel V., Reinehr R., Gatsios P., et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology: 2007; 45 3 695 704
88. Keitel V., Donner M., Winandy S., Kubitz R., Häussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun: 2008; 372 1 78 84
89. Keitel V., Ullmer C., Häussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem: 2010; 391 7 785 789
90. Nguyen A., Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell Signal: 2008; 20 12 2180 2197
91. Fiorucci S., Mencarelli A., Palladino G., Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci: 2009; 30 11 570 580
92. Drucker D. J., Philippe J., Mojsov S., Chick W. L., Habener J. F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A: 1987; 84 10 3434 3438
93. Kreymann B., Williams G., Ghatei M. A., Bloom S. R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet: 1987; 2 8571 1300 1304
94. Nakabayashi H., Nishizawa M., Nakagawa A., Takeda R., Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol: 1996; 271 5 Pt 1 E808 E813
95. Holst J. J. The physiology of glucagon-like peptide 1. Physiol Rev: 2007; 87 4 1409 1439
96. Potthoff M. J., Potts A., He T., et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol: 2013; 304 4 G371 G380
97. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med: 2002; 346 16 1221 1231
98. Targher G., Day C. P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med: 2010; 363 14 1341 1350
99. Sacks F. M., Alaupovic P., Moye L. A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation: 2000; 102 16 1886 1892
100. Monsour H. P. Jr, Frenette C. T., Wyne K. Fatty liver: a link to cardiovascular disease-its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J: 2012; 8 3 21 25
101. Neuschwander-Tetri B. A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology: 2010; 52 2 774 788
102. Unger R. H., Clark G. O., Scherer P. E., Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta: 2010; 1801 3 209 214
103. Zechner R., Zimmermann R., Eichmann T. O., et al. FAT SIGNALS-lipases and lipolysis in lipid metabolism and signaling. Cell Metab: 2012; 15 3 279 291
104. Wang Y. D., Chen W. D., Wang M., Yu D., Forman B. M., Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology: 2008; 48 5 1632 1643
105. Huang J., Iqbal J., Saha P. K., et al. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology: 2007; 46 1 147 157
106. Wang Y. D., Chen W. D., Moore D. D., Huang W. FXR: a metabolic regulator and cell protector. Cell Res: 2008; 18 11 1087 1095
107. He N., Park K., Zhang Y., Huang J., Lu S., Wang L. Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology: 2008; 134 3 793 802
108. Trauner M. A little orphan runs to fat: the orphan receptor small heterodimer partner as a key player in the regulation of hepatic lipid metabolism. Hepatology: 2007; 46 1 1 5
109. Vassileva G., Hu W., Hoos L., et al. Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. J Endocrinol: 2010; 205 3 225 232
110. Thomas C., Gioiello A., Noriega L., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab: 2009; 10 3 167 177
111. van der Poorten D., Samer C. F., Ramezani-Moghadam M., et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology: 2013; 57 6 2180 2188
112. Meier Y., Pauli-Magnus C., Zanger U. M., et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology: 2006; 44 1 62 74
113. Andreotti G., Menashe I., Chen J., et al. Genetic determinants of serum lipid levels in Chinese subjects: a population-based study in Shanghai, China. Eur J Epidemiol: 2009; 24 12 763 774
114. Acalovschi M., Tirziu S., Chiorean E., Krawczyk M., Grünhage F., Lammert F. Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls. Lipids: 2009; 44 6 521 526
115. Krawczyk M., Rusticeanu M., Grunhage F., Lammert F. Body mass index in the general population is associated with the common p.A444V variant of the ABC transporter for bile salts. Hepatology: 2009; 50 (4, Suppl): 1016A
116. Iwata R., Baur K., Stieger B., et al. Swiss Hepatitis C Cohort Study Group. A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci (Lond): 2011; 120 7 287 296
117. Zhang Y., Li F., Patterson A. D., et al. Abcb11 deficiency induces cholestasis coupled to impaired β-fatty acid oxidation in mice. J Biol Chem: 2012; 287 29 24784 24794
118. Takeuchi F., Katsuya T., Chakrewarthy S., et al. Common variants at the GCK, GCKR, G6PC2-ABCB11 and MTNR1B loci are associated with fasting glucose in two Asian populations. Diabetologia: 2010; 53 2 299 308
119. Rose C. S., Grarup N., Krarup N. T., et al. A variant in the G6PC2/ABCB11 locus is associated with increased fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads. Diabetologia: 2009; 52 10 2122 2129
120. Ferré P., Foufelle F. A new role for a metabolic star: AMP-activated protein kinase stimulates fat absorption. Cell Metab: 2011; 13 1 1 2
121. Chopra A. R., Kommagani R., Saha P., et al. Cellular energy depletion resets whole-body energy by promoting coactivator-mediated dietary fuel absorption. Cell Metab: 2011; 13 1 35 43
122. Hawley S. A., Gadalla A. E., Olsen G. S., Hardie D. G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes: 2002; 51 8 2420 2425
123. Figge A., Lammert F., Paigen B., et al. Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis. J Biol Chem: 2004; 279 4 2790 2799
124. Sundaram S. S., Whitington P. F., Green R. M. Steatohepatitis develops rapidly in transgenic mice overexpressing Abcb11 and fed a methionine-choline- deficient diet. Am J Physiol Gastrointest Liver Physiol: 2005; 288 6 G1321 G1327
125. Li Z., Agellon L. B., Allen T. M., et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab: 2006; 3 5 321 331
126. Fuchs C., Claudel T., Hallibasic E., et al Intrahepatic changes in bile acid composition protects bsep (abcb11) KO mice from hepatic inflammation in methionine choline deficient diet induced NASH. J Hepatol: 2013; 58 S1 S32
127. Geier A., Dietrich C. G., Grote T., et al. Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol: 2005; 43 6 1021 1030
128. Pizarro M., Balasubramaniyan N., Solís N., et al. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut: 2004; 53 12 1837 1843
129. Bechmann L. P., Kocabayoglu P., Sowa J. P., et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology: 2013; 57 4 1394 1406
130. Aron-Wisnewsky J., Gaborit B., Dutour A., Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect: 2013; 19 4 338 348
131. Drenick E. J., Fisler J., Johnson D. Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology: 1982; 82 3 535 548
132. Tilg H., Moschen A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology: 2010; 52 5 1836 1846
133. Inagaki T., Moschetta A., Lee Y. K., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A: 2006; 103 10 3920 3925
134. Neuschwander-Tetri B. A. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis: 2009; 13 4 649 665
135. Haedrich M., Dufour J. F. UDCA for NASH: end of the story? J Hepatol: 2011; 54 5 856 858
136. Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology: 2002; 36 3 525 531
137. Ratziu V., de Ledinghen V., Oberti F., et al. FRESGUN. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol: 2011; 54 5 1011 1019
138. Rodrigues C. M., Fan G., Ma X., Kren B. T., Steer C. J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest: 1998; 101 12 2790 2799
139. Ozcan U., Yilmaz E., Ozcan L., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science: 2006; 313 5790 1137 1140
140. Kars M., Yang L., Gregor M. F., et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes: 2010; 59 8 1899 1905
141. Lindor K. D., Kowdley K. V., Heathcote E. J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology: 2004; 39 3 770 778
142. Leuschner U. F., Lindenthal B., Herrmann G., et al. NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology: 2010; 52 2 472 479
143. Marschall H. U., Wagner M., Zollner G., et al. Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humans. Digestion: 2012; 86 3 244 249
144. Wagner M., Zollner G., Trauner M. Nuclear receptors in liver disease. Hepatology: 2011; 53 3 1023 1034
145. Fu L., John L. M., Adams S. H., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology: 2004; 145 6 2594 2603
146. Zhang S., Wang J., Liu Q., Harnish D. C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol: 2009; 51 2 380 388
147. Adorini L., Pruzanski M., Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today: 2012; 17 17-18 988 997
148. Mudaliar S., Henry R. R., Sanyal A. J., et al. Efficacy and safety of the farnesoid x receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology: 2013; 145 3 574, e1
149. Mencarelli A., Renga B., Distrutti E., Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol: 2009; 296 2 H272 H281
150. Hartman H. B., Gardell S. J., Petucci C. J., Wang S., Krueger J. A., Evans M. J. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res: 2009; 50 6 1090 1100
151. Hambruch E., Miyazaki-Anzai S., Hahn U., et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther: 2012; 343 3 556 567
152. Fuchs M. Non-alcoholic fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids: 2012; 2012 934396
153. Chennamsetty I., Claudel T., Kostner K. M., et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest: 2011; 121 9 3724 3734
154. McMahan R. H., Wang X. X., Cheng L. L., et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem: 2013; 288 17 11761 11770
155. Gordon S., Martinez F. O. Alternative activation of macrophages: mechanism and functions. Immunity: 2010; 32 5 593 604
156. Garg A., Grundy S. M. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med: 1994; 121 6 416 422
157. Suzuki T., Oba K., Futami S., et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch: 2006; 73 5 277 284
158. Goldberg R. B., Fonseca V. A., Truitt K. E., Jones M. R. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med: 2008; 168 14 1531 1540
159. Schwartz S. L., Lai Y. L., Xu J., et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord: 2010; 8 2 179 188
160. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA: 1984; 251 3 365 374
161. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA: 1984; 251 3 351 364
162. Taniai M., Hashimoto E., Tobari M., et al. Treatment of nonalcoholic steatohepatitis with colestimide. Hepatol Res: 2009; 39 7 685 693
163. Le T. A., Chen J., Changchien C., et al. San Diego Integrated NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology: 2012; 56 3 922 932
164. Nakatani H., Kasama K., Oshiro T., Watanabe M., Hirose H., Itoh H. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism: 2009; 58 10 1400 1407
165. Katsuma S,Hirasawa A, TsujimotoG. Bile acids promote glucagonlike peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. BiochemBiophys Res Commun 2005;329(1): 386-390